EMBL Courses and Conferences during the Coronavirus pandemic
With the onsite programme paused, many of our events are now being offered in virtual formats.
Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.
More information for participants of events at EMBL Heidelberg can be found here.
EMBL has taken the difficult decision to pause our programme of external courses and conferences. As a result, we are cancelling the course and apologise for the inconvenience.
Advances in cell and gene therapies (CGT) offer potential to transform medicine. Since the approval of the first two chimeric antigen receptor T cells (CAR-T) based therapies by the regulatory authorities in 2017, CAR-T have become one of the most promising personalized medicine in cancer treatment.
More than two decades after the first engineered T cells created in the laboratory, we have come to grasp the fact that each patient requires not only personalised treatment but also a unique manufacturing process to ensure that the right CAR-T cell arrives at the patient bed. From good science to manufacturing know-how, every step in between is critical and requires extensive knowledge in both basic and applied sciences. To name a few, T cell biology, gene delivery technologies, target identification, CAR design, facilities setup, manufacturing process development, process control, release criteria, etc., all aspects must come together, before a patient could be benefited from the scientific breakthrough.
This course, organized by Miltenyi Biotec and EMBL, will provide an unique overview, that participants will understand the vivid connections between basic science, cell manufacturing technologies and patient lives. The course aims to deliver an interactive repetition of the bench to bedside process — a unique and exciting course setting for basic and applied researchers in immunology and medicine.
Scientists in basic and medical research with a background in cellular and gene therapy who intend to initiate clinical applications in the near future; scientist with experience in stem cell transplantation who intend to work on advanced cell therapy manufacturing, and anyone intend to establish point-of-care CAR-T manufacturing.
- CAR-T cells as a tool — what has it taken to get it to the bedside
- Creating a patient specific CAR-T cell in R&D
- A review — the current state of effectiveness of CAR-T cells.
- Facilities setup and design
- Manufacturing & process control
- Quality control & in process control: How to assess safety of CAR-T cells prior to manufacturing and injection
- Released criteria
- To understand challenges in translating pre-clinical work to patient use — caveats and pitfalls.
- To understand the importance of CAR-T product quality and safety — a very different approach is needed when moving away from academic in vitro research